好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Therapeutic Inertia Correlates with the Level of Agreement on the Landscape of MS Treatments
Multiple Sclerosis
P1 - Poster Session 1 (5:30 PM-6:30 PM)
15-101
To evaluate the association between an individual’s agreement with a figure validated by MS experts & depicting the relative safety and efficacy of existing disease-modifying treatments (DMTs) for relapsing MS (figure: https://goo.gl/UrVRtd) and the prevalence of therapeutic inertia (TI) amongst neurologists from Argentina.
Neurologists with expertise in MS face the challenge of tailoring treatment decisions based on the optimal balance of safety and efficacy associated with an ever-changing landscape of therapies.

117 neurologists with MS expertise answered questions regarding the management of simulated clinical case-scenarios and a figure representing the safety and efficacy profiles of DMTs. Participants rated their agreement with the figure using an analog visual scale ranging from 0-10 (no-full agreement). TI was classified as a categorical (yes/no) and as a continuous variable by creating a score  ranging from 0 to 8. TI was defined as lack of treatment escalation when there was clear evidence of clinical and radiological activity (8 case-scenarios).

90 neurologists (76.9%) completed the study. TI was present in 74.4% of participants in at least one case scenario. The mean TI score (SD) was 1.7 (1.4). The mean level of agreement with the landscape figure was 8.1 (SD 1.9). Participants with lower agreement rate (≤6 out of 10) had a higher mean TI score compared to their counterparts (2.33 vs 1.60; p=0.10).

After adjusting for age, being an MS specialist, years of practice, and volume of patients seen per week, the agreement with the MS treatment figure was associated with lower incident risk of TI (OR 0.88; 95%CI 0.79-0.97).  

A higher level of agreement with a figure depicting the safety and efficacy of existing MS DMTs was independently associated with a lower incident risk of TI. These results suggest that a single question may be useful to identify neurologists prone to exhibiting TI.

Authors/Disclosures
Mariana Espinosa-Polanco
PRESENTER
No disclosure on file
Fabien S. Bakdache, PharmD No disclosure on file
No disclosure on file
Alonso Montoya, MD (Research and Development Roche Canada) No disclosure on file
Gustavo Saposnik, MD (Director, Clinical Outcomes & Decision Neuroscience Research Centre) Dr. Saposnik has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Saposnik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NIHSS. The institution of Dr. Saposnik has received research support from Roche. The institution of Dr. Saposnik has received research support from Heart and Stroke Foundation of Canada.